Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov:25:101530.
doi: 10.1016/j.tranon.2022.101530. Epub 2022 Sep 9.

Current landscape and perspective of oncolytic viruses and their combination therapies

Yinghan Su  1 , Changqing Su  2 , Lunxiu Qin  3
Affiliations
Review

Current landscape and perspective of oncolytic viruses and their combination therapies

Yinghan Su et al. Transl Oncol. 2022 Nov.

Abstract

Oncolytic virotherapy has become an important strategy in cancer immunotherapy. Oncolytic virus (OV) can reshape the tumor microenvironment (TME) through its replication-mediated oncolysis and transgene-produced anticancer effect, inducing an antitumor immune response and creating favorable conditions for the combination of other therapeutic measures. Extensive preclinical and clinical data have suggested that OV-based combination therapy has definite efficacy and promising prospects. Recently, several clinical trials of oncolytic virotherapy combined with immunotherapy have made breakthroughs. This review comprehensively elaborates the OV types and their targeting mechanisms, the selection of anticancer genes armed in OVs, and the therapeutic modes of action and strategies of OVs to provide a theoretical basis for the better design and construction of OVs and the optimization of OV-based therapeutic strategies.

Keywords: Anticancer mechanism; Cancer; Oncolytic virus; Therapeutic strategy; Tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest None declared.

References

    1. Heidbuechel J.P.W., Engeland C.E. Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies. J. Hematol. Oncol. 2021;14(1):63. doi: 10.1186/s13045-021-01075-5. Apr 16. - DOI - PMC - PubMed
    1. Heise C., Sampson-Johannes A., Williams A., McCormick F., Von Hoff D.D., Kirn D.H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 1997;3(6):639–645. doi: 10.1038/nm0697-639. Jun. - DOI - PubMed
    1. Proboka G., Tilgase A., Isajevs S., Rasa A., Alberts P. Melanoma unknown primary brain metastasis treatment with ECHO-7 oncolytic virus rigvir: a case report. Front. Oncol. 2018;8:43. doi: 10.3389/fonc.2018.00043. Feb 26. - DOI - PMC - PubMed
    1. Wei D., Xu J., Liu X.Y., Chen Z.N., Bian H. Fighting cancer with viruses: oncolytic virus therapy in China. Hum. Gene Ther. 2018;29(2):151–159. doi: 10.1089/hum.2017.212. Feb. - DOI - PubMed
    1. Ferrucci P.F., Pala L., Conforti F., Cocorocchio E. Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma. Cancers. 2021;13(6):1383. doi: 10.3390/cancers13061383. (Basel)Mar 18. - DOI - PMC - PubMed